Previous studies in the serglycin proteoglycan deficient mouse strain has shown that the deletion impacts on the secretion of many tumour growth and metastasis promoting agents e. g. matrix metalloproteinases (MMPs), tumour necrosis factor (TNF)-alpha, platelet derived growth factor (PDGF), tissue type plasminogen activator, as well as several cytokines and chemokines[5, 10, 49, 50]. Here, SRGN is linked to neoplasm.